STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] VOLITIONRX LTD SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

VolitionRx (VNRX): Ownership update — Armistice Capital, LLC and Steven Boyd filed Schedule 13G/A (Amendment No. 4) reporting beneficial ownership of 9,380,425 shares of VolitionRx common stock, representing 8.72% of the class. The filing reports shared voting and dispositive power over 9,380,425 shares and no sole voting or dispositive power.

The percentage is based on 107,595,421 shares outstanding as of August 7, 2025, as disclosed by the company. Armistice Capital is the investment manager to the direct holder (Armistice Capital Master Fund Ltd.), and Steven Boyd is Armistice Capital’s managing member. The securities are certified as held in the ordinary course of business and not for the purpose of changing or influencing control.

Positive
  • None.
Negative
  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What ownership stake in VNRX did Armistice Capital report?

They reported beneficial ownership of 9,380,425 shares, or 8.72% of VolitionRx’s common stock.

What voting and dispositive powers were disclosed for VNRX?

The filing shows shared voting power: 9,380,425 and shared dispositive power: 9,380,425; sole power: 0 for both.

What share count did VNRX have outstanding for the percentage calculation?

The ownership percentage is based on 107,595,421 shares outstanding as of August 7, 2025.

Who are the reporting persons in the VNRX Schedule 13G/A?

The reporting persons are Armistice Capital, LLC and Steven Boyd.

Was the VNRX stake reported as a control position?

No. The securities are certified as held in the ordinary course of business and not for changing or influencing control.

Who directly holds the reported VNRX shares?

The direct holder is Armistice Capital Master Fund Ltd.; Armistice Capital is its investment manager.

What is the event date for the VNRX ownership report?

The date of event requiring the filing is September 30, 2025.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

42.85M
98.10M
17.84%
22.29%
0.28%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON